World Orphan Drug Congress Europe 6.-8.November 2018 I CROWNE PLAZA BARCELONA
10.10.2018
Dear Daniela,
Come and join 2 days of cell & gene therapy for rare diseases at the 9th World Orphan Drug Congress (6th–8th November) in Barcelona!
Key Topics: Clinical Advancements, Manufacture, Commercialisation and Pricing & Reimbursement
Creating research pipelines that are robust enough for gene therapy to become a reality
Preparing for later stage trials and commercialisation
Overcoming the key commercial challenges facing gene therapy products
How can gene therapy companies make their manufacturing process more cost effective and sustainable?
Innovative payment models for cell & gene therapies
Patient collaboration
VIEW THE AGENDA
REGISTER NOW
Key Speakers:
Dr Andreas Busch, Chief Scientific Officer, Head of Research and Development, Shire
Dr Sander van Deventer, CSO, UniQure
Dr Gregory LaRosa, Senior Vice President & Head of Scientific Strategy, Rare Disease RU, Pfizer, Inc.,
Dr Alexander Natz, Secretary General, EUCOPE
Sarah Pitluck, Head, Global Pricing & Reimbursement, Spark Therapeutics
Dr Emanuele Ostuni, Head of Europe, Cell and Gene Therapy, Novartis Oncology Region Europe
Karen Aiach, Founder, Chief Executive Officer, Founder and CEO, Lysogene
Nerissa C. Kreher, MD, MBA, CMO, AvroBio
Dr Frederic Revah, Chief Executive Officer, Genethon & President, Yposkesi
James Christie, SVP Manufacturing & Supply Chain, MeiraGTx
Dr Birgitte Volck, Senior Vice President & Head of Rare Diseases R&D, GSK
Dr Tuyen Ong, CDO, Nightstar Therapeutics
Dr Jerome Rossert, Vice President, General Medicine, Global Clinical Development, Vertex Pharmaceutica
Dr Michael Binks, VP, Rare Disease Clinical Research, Pfizer
REGISTER NOW
REGISTER NOW to meet these key decision makers, and to be part of these vital discussions!
You do not want to miss out!
Looking forward to meeting you in November,
Nadia Konneh, MChem
Conference Manager
World Orphan Drug Congress
Email: nadia.konneh@Terrapinn.com
Tel: +44 (0) 207 092 1053
Our Advisory Board
Yann Le Cam, Chief Executive Officer, EURORDIS
Dr Alexander Natz, Secretary General, EUCOPE
Dr Bruno Sepodes, Chair of COMP, EMA
Alastair Kent, Former Director, Genetic Alliance UK
Professor Michael Linden, Former VP Gene Therapy & Head, GMI, Pfizer
Wills Hughes-Wilson, Head of Patient Access & Commercial Planning, Mereo BioPharma
Dr Ségolène Aymé, Founder of Orphanet, Emeritus Research Director, INSERM
Sheela Upadhyaya, Associate Director Highly Specialised Technologies, NICE
Dr Carlo Incerti, SVP, Head of Global Medical Affairs, CMO, Genzyme, A Sanofi Company
Dr Mathew Pletcher, Head of Rare Disease Discovery, Roche
Dr M Ken Kengatharan, Managing Director, Atheneos
Rick Thompson, CEO, Findacure
Dr Birgitte Volck, SVP, Head of R&D Rare Diseases, GSK
Dr Pedro Franco, Former Scientific Administrator, EMA
Anna Bucsics, Project Advisor, MoCA
Josie Godfrey, Former Associate Director, NICE
Unsubscribe from this list
or
Manage your preferences
This email was sent to: dippold.daniela@gmx.de
Terrapinn respects your privacy
Terrapinn Holdings Ltd,
Wren House, 43 Hatton Garden, London, EC1N 8EL, UK
Tel: +44 (0)20 7092 1000 | Email: enquiry.uk@terrapinn.com